Diclofenac diethylamine 是一种有效的,非选择性抗炎剂,为COX的抑制剂,在 CHO 细胞中,对人 COX-1 和 COX-2 的IC50值分别为 4 和 1.3 nM。Diclofenac diethylamine 对绵羊 COX-1 和 COX-2 的IC50值分别为 5.1 μM,0.84 μM。Diclofenac diethylamine 通过活化 caspase 级联反应来诱导神经干细胞凋亡 (apoptosis)。
生物活性 | Diclofenac diethylamine is a potent and nonselective anti-inflammatory agent, acts as aCOXinhibitor, withIC50s of 4 and 1.3 nM for humanCOX-1andCOX-2in CHO cells[1], and 5.1 and 0.84 μM for ovineCOX-1andCOX-2, respectively[2]. Diclofenac diethylamine inducesapoptosisof neural stem cells (NSCs) via the activation of thecaspasecascade[3]. |
IC50& Target[1][2] | Human COX-2 1.3 nM (IC50, in CHO cells) | Human COX-1 4 nM (IC50, in CHO cells) | Ovine COX-2 0.84 μM (IC50) | Ovine COX-1 5.1 μM (IC50) |
|
体外研究 (In Vitro) | Diclofenac effectively blocks COX-1 mediated prostanoid production from U937 cell microsomes, with an IC50of 7±3 nM[1]. Diclofenac (1-60 μM; 1 day) induces neural stem cells (NSCs)death in a concentration-dependent manner[3]. Diclofenac (10-60 μM; 6 hours) increases the expression of cleaved (activated) caspase-3[3].
Cell Viability Assay[3] Cell Line: | Neural stem cells (NSCs) | Concentration: | 1, 3, 10, 30, 60 μM | Incubation Time: | 1 day | Result: | Induction of cell death was concentration-dependent and the effect was not saturated at a concentration of up to 60 μM. |
Western Blot Analysis[3] Cell Line: | Neural stem cells (NSCs) | Concentration: | 10, 30 or 60 μM | Incubation Time: | 6 hours | Result: | The activation of caspase-3 was increased in a concentration-dependent manner. |
|
体内研究 (In Vivo) | Diclofenac (3 mg/kg, b.i.d., for 5 days) significantly increases faecal51Cr excretion in rats, and such effect is also observed in squirrel monkeys after administrated of 1 mg/kg twice daily for 4 days[1]. Diclofenac (10 mg/kg; administered via oral route just prior to induction of inflammation) shows in vivo anti-inflammatory activity in Wistar rats[1].
Animal Model: | Male Sprague-Dawley rats (150±200 g)[1] | Dosage: | 3 mg/kg | Administration: | Oral administration, b.i.d., for 5 days | Result: | Resulted in a significant increase in faecal51Cr excretion. |
Animal Model: | Wistar rats (150-175 g) bearing Formalin-induced rat foot paw edema model[2] | Dosage: | 10 mg/kg | Administration: | Administered via oral route just prior to induction of inflammation | Result: | Showed in vivo anti-inflammatory activity (% edema inhibition=29.2, 1 h; 22.2, 3 h; 20, 6 h). |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
溶解性数据 | In Vitro: DMSO : 150 mg/mL(406.18 mM;Need ultrasonic) 配制储备液 1 mM | 2.7079 mL | 13.5395 mL | 27.0790 mL | 5 mM | 0.5416 mL | 2.7079 mL | 5.4158 mL | 10 mM | 0.2708 mL | 1.3539 mL | 2.7079 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (6.77 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (6.77 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (6.77 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|